What You Will Learn from This Brochure:

Why CNS DMPK Requires a Different Approach

Understand the challenges of interpreting total brain concentration data and the importance of evaluating unbound drug exposure.

Measuring Unbound CNS Exposure with Brain Microdialysis

Explore how our in vivo microdialysis platform enables measurement of unbound drug concentrations in brain extracellular fluid, providing insights into pharmacologically relevant CNS exposure profiles.

Mapping Drug Distribution Across Brain Regions

Learn how region-specific brain tissue collection and quantitative analysis characterize drug distribution patterns across key brain regions, supporting CNS exposure assessment and PK interpretation.

Determining the Key Parameter – K_p,uu

Learn how we calculate and interpret the unbound brain-to-plasma partition coefficient, an essential metric for selecting and prioritizing CNS-penetrant candidates.

Building an Integrated CNS DMPK Workflow:

See how brain distribution analysis, microdialysis, CSF PK assessment, and ADME profiling can be integrated to support CNS drug development programs.

Why Download This Brochure?

Address Key CNS DMPK Challenges:

Gain insights into specialized approaches designed to characterize CNS exposure and support compound optimization.

Support Data-Driven Development Decisions

Learn how CNS PK parameters, including Kp,uu, can provide valuable guidance during candidate evaluation and optimization.

Explore Our Platform Applications

The brochure includes an outline of our integrated strategy and a case study demonstrating the application of our platform to solve a real-world DMPK challenge.

Download the brochure to explore our capabilities. Contact our DMPK team today to discuss a tailored solution for your project.

You might be interested in...